Genetic structure of the healthy donor effect

Jonna Clancy*[1,2], Jarkko Toivonen[2], Jouni Lauronen[2], Satu Koskela[1], Jukka Partanen[2], FinnGen[3], Mikko Arvas[2], Jarmo Ritari[2]

[1] Finnish Red Cross Blood Service, Blood Service Biobank, Vantaa, Finland

[2] Research & Development, Finnish Red Cross Blood Service, Helsinki, Finland

[3] List of FinnGen members is available as a supplementary file

* jonna.clancy@veripalvelu.fi

Abstract

The healthy donor effect (HDE) refers to the observed lower mortality rate among blood donors compared to the general population. While HDE arises due to healthier individuals being more likely to be able to donate, the extent to which it is influenced by genetic differences remains largely unclear. To elucidate the genetic basis of HDE, we conducted a genome-wide association study (GWAS) involving 53,688 active blood donors with extensive donation histories and 228,060 controls from biobank cohorts within the FinnGen project. Our results identified 2,973 genome-wide significant loci associated with several health-related endpoints and levels of proteins and laboratory values. The associated loci related not only to blood groups but also to predisposition to infections and somatic and mental diseases, suggesting that HDE genetics extends beyond blood donation eligibility criteria. In conclusion, in this study we show that HDE is partially explained by genetic factors affecting various disease categories.

Keywords: blood donor, biobank, healthy donor effect, GWAS, blood group, HLA

Introduction

Blood donors are a highly selected population due to the health status criteria they must meet to be eligible to donate blood. Along with a general survey of the donors' current state of health, basic restrictions on blood donation suitability include serious illnesses such as severe cardiovascular conditions, cancer and epilepsy[1]. Some conditions that restrict blood donation suitability have a strong well-known genetic background, such as the association of *HLA* genes in type 1 diabetes (T1D)[2] or in certain autoimmune diseases[3–5]. As a minimum hemoglobin level is required for donation eligibility, genetic variants affecting iron and hemoglobin levels (may) also result in donor selection. In addition to the blood donation eligibility criteria, the healthier lifestyle in general followed by the blood donors and self-selection caused by various factors, e.g. common cold, results in a known phenomenon, *healthy donor effect*, HDE, a form of membership bias, which can lead to detrimental effects in a research setting if not taken into account[6].

Comprehensive selection of different blood groups, and especially a sufficient amount of emergency blood type O RhD neg suitable for most recipients, are basic requirements in blood banks. Due to the high need for emergency blood O RhD neg and strong immunogenicity of certain blood group antigens such as ABO, Rh and Kell[7–10], donor recruitment is partially based on blood group genotype and results in enrichment of certain blood group antigens in a blood donor pool. Well-known associations between ABO blood group antigens and cardiovascular conditions exist, more precisely between red cell antigen O and reduced thromboembolic diseases[11,12]. Risk for bleeding disorder, von Willebrand disease, is known to be higher among individuals with red cell O antigen[13]. Pregnancy-induced hypertension has been previously described to occur more in RhD positive individuals[12]. Moreover, in hemochromatosis, blood donation diminishes the symptoms, and donors with hemochromatosis-associated gene variants are known to be enriched in the blood donor population[14].

71 Blood donor samples have been used as a healthy control cohort in genetics and biomedical
72 research due to their commitment and willingness to participate[15]. Voluntary and frequent blood
73 donation offers unique opportunities for longitudinal sampling. In addition, blood donors exhibit
74 positive attitudes toward the use of their samples and data in scientific research, if not directly
75 required in patient care[16,17]. However, the enrichment of genetic variants with known disease
76 associations or biological functions may result in unpredicted effects in biomedical research. To
77 reveal the genetics of blood donation and to understand the possible genetic selection leading to the
78 HDE, we conducted a genome-wide association study (GWAS) between active blood donors of the
79 (Finnish Red Cross) Blood Service Biobank and FinnGen cohort (Figure 1).

80 To the best of our knowledge, no previous genome studies have focused on the possible selection
81 bias caused by blood groups, health questionnaire-based requirement, and self-selection of blood
82 donors. In our analysis, we found altogether 2,973 genome-wide significant associations in 46
83 distinct fine-mapped loci. Genetic correlation analysis revealed strong negative correlation between
84 blood donorship and diseases such as mental disorders, pain disorders, cardiovascular diseases,
85 addiction disorders, autoimmune disorders, and Alzheimer's disease. *HLA* association analysis
86 confirmed the enrichment of hemochromatosis-related and protective autoimmune *HLA* alleles and
87 the lower occurrence of autoimmune-related *HLA* alleles in the blood donor population and
88 indicated a risk SNP tagging both hemochromatosis and autoimmune related *HLA* alleles. The
89 genome-wide significant variants also associated with 181 plasma protein level alterations and
90 several clinical blood laboratory value measurements. The results of this study demonstrate the
91 genetic basis of the HDE, which is not limited to immediate blood donorship inclusion criteria.

92



Figure 1. We conducted a GWAS on 53,688 blood donors and 228,060 controls (FinnGen). Genome-wide significant associations were fine-mapped and used for downstream analyses. Genetic correlations between 2,470 FinnGen phenotypes and blood donorship were calculated based on the GWAS summary statistics. Additionally, we imputed red cell antigens and tested their association with blood donorship. Previously imputed HLA alleles in FinnGen were similarly used for association analysis. We further used quantitative trait loci analysis to examine the association of fine-mapped and MHC lead variants with blood protein levels and clinical laboratory measurements. *Created in BioRender. Clancy, J. (2025) https://BioRender.com/a70o677*

Results

The overall study design is shown in Figure 1. Table 1 provides a detailed description of the study population characteristics and differences in diagnoses between the two cohorts. Blood donors, both male and female, were generally younger and taller than the controls. Additionally, male blood donors were heavier than their control counterparts. The blood donor cohort had a higher proportion of female participants. In all diagnosis categories, the prevalence of disease was

significantly higher in the control group compared to the blood donors, except for the category 'XVI Certain conditions originating in the perinatal period,' where a higher prevalence of cases was observed among blood donors of both sexes. The FinnGen control cohort included donors from hospital biobanks, population cohorts, and occupational health settings (Supplementary Table 1).

	Females		Males	
	Blood donors	FinnGen	Blood donors	FinnGen
Median age at sampling, years (IQR)	44.47 (18.2-70.8)	62.7 (36.2-89.2)	50.26 (25.5-75.0)	70.46 (51.3-89.6)
Sex, n (%)	32,460 (60.46)	120,279 (52.74)	21,228 (39.54)	107,781 (47.26)
Median weight, kg (IQR)	72 (54-90) [a]	72 (51-93) [a]	86 (68-104)	84 (64-104)
Median height, cm (IQR)	167 (159-175)	164 (156-172)	180 (171-189)	177 (168-186)
Median BMI (IQR)	25.83 (19.3-32.4)	26.64 (19.1-34.2)	26.58 (21.6-31.6)	26.88 (21.2-32.6)
Number of diagnoses per FinnGen endpoint category (%)[b]				
I Certain infectious and parasitic diseases (AB1)	7,466 (23)	47,901 (39.82)	5,565 (26.22)	48,487 (44.99)
II Neoplasms from cancer register (ICD-O-3)	968 (2.98)	34,299 (28.52)	791 (3.73)	38,891 (36.08)
II Neoplasms from hospital discharges (CD2)	6,960 (21.44)	67,026 (55.73)	2,804 (13.21)	52,708 (48.9)
III Blood and immune system (D3)	964 (2.97)	17,017 (14.15)	534 (2.52)	15,606 (14.48)
IV Endocrine, nutritional and metabolic (E4)	10,269 (31.64)	83,780 (69.65)	3,029 (14.27)	58,530 (54.3)
IX Circulatory system (I9)	6,276 (19.33)	69,429 (57.72)	4,587 (21.61)	78,876 (73.18)
V Mental and behavioural disorders (F5)	7,871 (24.25)	42,676 (35.48)	3,648 (17.18)	33,080 (30.69)
VI Nervous system (G6)	6,431 (19.81)	54,710 (45.49)	4,501 (21.2)	51,142 (47.45)
VII Eye and adnexa (H7)	8,088 (24.92)	58,567 (48.69)	4,660 (21.95)	47,174 (43.77)
VIII Ear and mastoid process (H8)	5,316 (16.38)	29,249 (24.32)	3,893 (18.34)	26,561 (24.64)
X Respiratory system (J10)	14,408 (44.39)	69,022 (57.38)	11,532 (54.32)	69,209 (64.21)
XI Digestive system (K11)	27,542 (84.85)	106,938 (88.91)	17,037 (80.26)	90,482 (83.95)
XII Skin and subcutaneous tissue (L12)	7,710 (23.75)	43,402 (36.08)	4,096 (19.3)	32,486 (30.14)
XIII Musculoskeletal and connective tissue (M13)	13,715 (42.25)	83,931 (69.78)	9,118 (42.95)	68,570 (63.62)
XIV Genitourinary system (N14)	17,334 (53.4)	91,665 (76.21)	4,463 (21.02)	49,729 (46.14)
XIX Injury, poisoning, external (ST19)	15,936 (49.09)	73,725 (61.29)	13,051 (61.48)	70,375 (65.29)
XV Pregnancy, childbirth and the puerperium (O15)	20,560 (63.34)	86,799 (72.16)	0 (0)	0 (0)
XVI Perinatal period (P16)	535 (1.65)	1,000 (0.83)	263 (1.24)	514 (0.48)
XVII Congenital malformations (Q17)	2,018 (6.22)	10,032 (8.34)	1,231 (5.8)	7,258 (6.73)
XVIII Abnormal clinical and laboratory findings (R18)	16,800 (51.76)	93,458 (77.7)	9,125 (42.99)	80,419 (74.61)
XX External causes of mortality (VWXY20)	13,025 (40.13)	64,874 (53.94)	10,741 (50.6)	62,034 (57.56)
XXI Contact with health services (Z21)	24,581 (75.73)	10,4068 (86.52)	10,544 (49.67)	72,915 (67.65)
XXII Codes for special purposes (U22)	1,417 (4.37)	5,906 (4.91)	595 (2.8)	4,310 (4)

[a] Not significant
[b] Shortened for clarity

Table 1. Characteristics of the study cohorts. Age, sex, height, weight, BMI and FinnGen endpoint categories in blood donors and FinnGen control cohorts are shown.

Genome-wide association analysis

Genome-wide association analysis revealed 2,973 significant ($p < 5x10^{-8}$) SNPs associated with blood donorship. After fine-mapping, 5 coding (4 missense and 1 inframe deletion) and 36 non-coding

119 variants were detected (Figure 2A). In addition to these 41 variants, 5 non-coding lead variants in the
120 extended MHC region (Figure 2B and C) were included in the downstream analyses (Table 2).

121 The strongest genome-wide associations were seen in variants related to blood group antigens:
122 rs55794721-A ($p = 8.88x10^{-89}$) in chr 1, rs687621-A ($p = 5.70x10^{-81}$) on chr 9 in *ABO* gene, and
123 rs8176058-A ($p = 1.16x10^{-31}$) on chr 7 in *KEL* gene (Figure 1A, Table 2).

124 Despite of the adjustment of the GWAS for BMI, we observed significant GWAS variants influencing
125 height, weight, and BMI. rs66781921-T, an inframe deletion variant in chr 2, previously shown to
126 have a negative association with height, weight and body mass index[18], was rarer in blood donors
127 (beta = -1.97, $p = 1.89 \times 10^{-11}$). The missense variant rs34811474-A, previously shown to be
128 negatively associated with body mass index[18], was found to be more frequent in blood donors (beta
129 = 0.064, $p = 1.21 \times 10^{-12}$). Variants rs10947114-T (beta = -0.055, $p = 2.88 \times 10^{-09}$,), rs3130906-A (p =
130 5.17×10^{-11}, beta = -0.055) and rs4713637-C ($p = 1.39 \times 10^{-08}$, beta = -0.047), previously described to
131 be associated with spondylopathies and celiac disease[18], were negatively associated with blood
132 donorship. A rare intron variant in chromosome 3, rs528492111-T, previously shown to have a weak
133 association to benign neoplasm of conjunctiva[18], was more frequent in blood donors (beta = 1.87, p
134 $= 4.09 \times 10^{-10}$). All the fine-mapped and MHC lead variants in the are listed in Table 2.



Figure 2. Results of the genome-wide association study (GWAS) for blood donorship. **a)** Manhattan plot of the whole genome. **b)** Extended major histocompatibility (MHC) region on chromosome 6. **c)** MHC association adjusted for type 1 diabetes (T1D). In panel **a)**, red dots indicate fine-mapped variants. In panels **b)** and **c)**, the highest variant in each peak reaching genome-wide significance ($p < 5 \times 10^{-8}$) is highlighted in red. For variants with p-values $\leq 5 \times 10^{-9}$, the target gene or nearest gene is named. The horizontal line represents significance threshold of 5×10^{-8}.

chr	pos	Effect allele	rs number	pval	beta	Most severe	Gene most severe
2	231460727	T	rs66781921	1,89E-11	-1,973	inframe deletion	NCL
11	5226799	A	rs1135071	2,93E-13	-0,573	missense variant	HBB
17	58358769	T	rs199598395	1,55E-25	-0,383	missense variant	RNF43
7	142957921	A	rs8176058	1,16E-31	-0,327	missense variant	KEL
5	174443703	C	rs191302298	3,89E-08	-0,292	intron variant	LINC01411
8	105038155	C	rs10096658	1,35E-08	-0,277	intron variant	ZFPM2
19	5149612	A	rs62113181	8,06E-09	-0,135	intron variant	KDM4B
4	37135112	C	rs75738358	4,89E-08	-0,080	intergenic variant	MIR4801*
7	101559560	A	rs12539059	5,68E-09	-0,071	downstream gene variant	COL26A1
6	32636375	G	rs9272324	1,36E-16	-0,064	intron variant	HLA-DQA1*
19	18707615	AT	rs36035346	5,48E-09	-0,062	intron variant	CRTC1
7	23484043	A	rs60678519	1,06E-08	-0,055	downstream gene variant	AC079780 ,1
6	30934404	T	rs10947114	2,88E-09	-0,055	intron variant	SFTA2*
6	31457404	A	rs3130906	5,17E-11	-0,055	intron variant	HCP5*
10	77157477	A	rs80319585	1,92E-08	-0,055	intron variant	KCNMA1
7	82855734	A	rs7795945	1,28E-09	-0,049	intron variant	PCLO
2	186695046	T	rs34483988	1,65E-08	-0,049	intron variant	FAM171B
3	18717009	T	rs6775319	2,17E-09	-0,048	intron variant	SATB1-AS1
10	105646256	A	rs7907026	4,63E-10	-0,048	intergenic variant	SORCS3*
1	153658595	A	rs3806234	5,16E-09	-0,047	upstream gene variant	SNAPIN
6	33602120	C	rs4713637	1,39E-08	-0,047	intergenic variant	LINC00336*
18	52600634	C	rs62083414	5,35E-09	-0,046	intron variant	DCC
4	19015485	A	rs207350	3,03E-08	-0,045	intergenic variant	LCORL*
17	48880334	C	rs594398	1,18E-08	-0,044	intron variant	SUMO2P17
12	38272211	T	rs10880819	2,64E-08	0,043	downstream gene variant	RF00019
2	71295511	CA	rs35440643	4,54E-08	0,044	intron variant	ZNF638
2	26992548	A	rs10166897	1,57E-08	0,044	intron variant	MAPRE3
15	75059054	TG	rs113236240	6,53E-09	0,045	intron variant	PPCDC
9	16695862	CAAGCA	rs55763604	2,84E-08	0,049	intron variant	BNC2
1	27087829	T	rs55732343	2,31E-10	0,049	regulatory region variant	SLC9A1*
6	26071867	C	rs9968910	1,12E-09	0,050	intergenic variant	HIST1H1C*
17	67991393	T	rs5821444	7,98E-09	0,051	3 prime UTR variant	C17orf58
16	13464582	C	rs6498415	5,47E-10	0,053	intron variant	U91319 ,1
16	90023620	G	rs12444334	1,51E-09	0,053	intron variant	GAS8
2	59856883	A	rs11675100	3,88E-09	0,054	intron variant	AC007100 ,1
6	17127475	A	rs9367942	3,81E-08	0,055	intron variant	STMND1
12	57289173	T	rs61937595	1,25E-08	0,062	intron variant	R3HDM2
4	25407216	A	rs34811474	1,21E-12	0,064	missense variant	ANAPC4
1	66016472	C	rs1500956	5,14E-10	0,075	intron variant	PDE4B
6	102401219	C	rs77448558	1,28E-08	0,078	intergenic variant	GRIK2*
7	97662657	T	rs10268629	1,71E-09	0,078	intergenic variant	TAC1*
13	50130043	T	rs75350584	1,58E-08	0,094	intron variant	DLEU1
9	133261662	A	rs687621	5,70E-81	0,147	intron variant	ABO
1	25235176	A	rs55794721	8,88E-89	0,157	upstream gene variant	SYF2
19	50410043	C	rs118101548	1,90E-08	0,299	intron variant	POLD1
3	49008876	T	rs528492111	4,09E-10	1,875	intron variant	WDR6

Table 2. Fine-mapped (41) and MHC lead variants (5) from blood donorship GWAS. P-value, effect size, the predicted most serious effect type and target gene for each variant are shown. Variants are

ordered according to association effect size. In case the target gene is not known, the nearest gene is indicated by asterisk (*).

Genetic correlation

To assess the genetic similarity between blood donors and various disease phenotypes, we performed a genetic correlation analysis comparing the blood donor GWAS with over 2,400 FinnGen core endpoint GWAS results.

Altogether 593 phenotypes were negatively correlated with blood donorship (FDR < 0.05, Supplementary File 2). Height and hemoglobin were the only phenotypes showing weak positive correlation with blood donorship, r_g = 0.07 and r_g = 0.18, respectively (Figure 3), despite that the blood donorship GWAS had been adjusted for BMI.

Blood donorship was negatively correlated with r_g < -0.5 to 30 phenotypes (Supplementary File 2). The strongest negative correlation (r_g < -0.6) in blood donors was seen with 'Anemias' (r_g = -0.66, FDR = 2.81 x 10^{-112}), ´Other reaction to severe stress and adjustment disorders´ (r_g = -0.64, FDR = 3.36 x 10^{-40}) and ´Other disorders of teeth and supporting structures´ (r_g = -0.62, FDR = 2.74 x 10^{-03}). Moderate negative correlation (r_g < -0.2) with malignancy-related phenotypes was observed. In addition, negative correlation with blood donorship was observed for addiction phenotypes such as smoking dependency (r_g = -0.29, FDR = 1.57 x 10^{-05}), alcohol dependence (r_g = -0.31, FDR = 8.26 x 10^{-20}) and substance abuse (r_g = -0.39, FDR = 2.88 x 10^{-45}). Expectedly blood donors displayed protective correlation towards autoimmune related phenotypes. Protective correlation was also observed with autoimmune diseases in general (r_g = -0.33, FDR = 1.87 x 10^{-52}), e.g. 'Irritable bowel syndrome' displayed strong negative correlation (r_g = -0.50, FDR = 4.05 x 10^{-26}). A wide variety of mental illnesses (in total 49 phenotypes) were negatively correlated with blood donorship. The strongest mental illness-related phenotype with negative genetic correlation was 'Mental disorders, not otherwise specified' (rg = -0.59, FDR 0.001). Another example of phenotypes not directly restricted

174 by blood donation eligibility criteria but with relatively strong negative correlation towards blood
175 donorship were infectious phenotypes, such as acute bronchitis (r_g = -0.58, FDR = 1.76 x 10^{-16}), viral
176 hepatitis (r_g = -0.51, FDR = 1.88 x 10^{-7}) and 'other or unspecified bacterial infection' (r_g = -0.50, FDR =
177 1.83 x 10^{-09}) (Figure 3, Supplementary File 2). Lastly, phenotypes not directly prohibited by blood
178 donation eligibility criteria, but which undeniably affect donation suitability or donor's knowledge of
179 their current state of health, such as Alzheimer's disease (r_g = -0.24, FDR = 0.03), were also
180 negatively correlated with blood donorship.

181



182

183 **Figure 3**. Genetic correlations of selected phenotypes against blood donorship phenotype. Each
184 correlation is statistically significant at an FDR threshold of 0.05. The proportion of genetic variance
185 shared between blood donorship, and a given phenotype (r_g) is shown on the x-axis. Error bars

represent the 95% confidence intervals. Apart from height and hemoglobin, all the phenotypes were negatively correlated with blood donorship.

Blood group antigen-related associations

To quantify the enrichment of blood group antigens among blood donors, we evaluated the association between imputed red cell antigens and blood donorship using a logistic regression model. The model revealed a strong negative association for the Kell, RhD, and AB blood group antigens, and a positive association for the O blood group antigen (Figure 4a). The effect sizes for the red cell antigens and other GWAS covariates are provided in Supplementary File 2.

We further analyzed the blood group related significant fine-mapped GWAS variants in chromosomes 1, 7 and 9 with linear regression models. The lead variant in chromosome 1, rs55794721-A, was associated with the Rh blood group system (previously shown to be associated with height[18]). Rh antigens E, C and D were negatively associated with rs55794721-A, whereas e and c antigens of the most common Rh negative haplotype in the Caucasoid population, dce[8], were positively associated with rs55794721-A (Figure 4b). 91% of individuals positive for Rh c and e alleles and had no Rh D, C or E alleles, were homozygotes (dosage value > 1.5) for rs55794721-A. rs55794721-A is in LD[19] (R^2 = 0.39) with variant rs586178-C tagging certain RhCE blood group alleles[20]. Lead variant in chromosome 7, rs8176058-A, a known tag SNP for Kell blood group antigen[20] was positively associated with K antigen (Figure 4c). The lead variant in chromosome 9, rs687621-A[19], is in strong LD, R^2 = 1 with blood group O tagging SNP rs687289-G[21]. We saw a strong positive association of rs687621-A with blood group antigen O, a positive association with blood group antigen B and a negative association with blood group antigen AB (Figure 4d).



Figure 4. Association of blood group antigens with **a)** blood donorship and the fine-mapped lead variants **b)** rs55794721-A, **c)** rs8176058-A, and **d)** rs687621-A on chromosomes 1, 7, and 9, respectively. The magnitude of the association is represented on the x-axis as log odds ratios for the logistic regression of blood donorship and regression coefficients for the linear regression of the variant dosage.

HLA allele associations

Because of the known strong role of the *HLA* region in immunology and the predisposing risk of certain *HLA* alleles in autoimmunity[2–5,22], we performed an association study with imputed *HLA*

218 alleles for blood donor endpoint. *HLA* association analysis for blood donorship (Figure 5, upper
219 panel) revealed a negative association with *HLA*-alleles in linkage with the well-known T1D risk
220 genotype *HLA-DQ2/DQ8*. A known risk allele for ankylosing spondylitis[22] *HLA-B*27:05* was negatively
221 associated with blood donorship. Positive association was seen with HLA alleles previously shown to
222 be associated with HFE C282Y allele in Finland[14] or HLA class II alleles with known protection from
223 T1D[23]. To fine-map the MHC GWAS signal (Figure 2b), we adjusted the analysis with the MHC lead
224 variant on chromosome 6 in *HLA-DQA1*, rs9272324-G (Figure 5, middle panel). We found that
225 controlling for rs9272324-G decreased the effect sizes of the above-mentioned *HLA* alleles in linkage
226 with *HLA-DQ8* and *HLA-B*27:05* and increased the p-values of the above mentioned HFE C282Y
227 related *HLA*-alleles below the significance level. When adjusted for the lead *HLA*-allele, *DRB1*04:01*
228 (Figure 5, lower panel), *HLA-B*27:05* and *HLA-C*02:02* in LD (r^2 = 0.3) with *HLA-B*27:05* and HLA-
229 alleles in linkage with HLA-DQ2 were negatively associated with blood donorship. Adjustment with
230 *HLA-DRB1* revealed also the negative association of *HLA-B*08:01*, a known *HLA-B* allele in linkage
231 with *HLA-DQ2* in Finland, with blood donorship (Figure 5, lower panel). In *HLA-DRB1*04:01* adjusted
232 analysis, HFE C282Y-related *HLA* alleles *B*07:02*, *DRB1*15:01*, *DQA1*01:02* and *DQB1*06:02* were
233 positively associated with blood donorship, but with less significant p-values than in *HLA*-association
234 analysis without any additional adjustment. The most significant results of the HLA association
235 analysis are shown in Supplementary Table 2 and full list of results in Supplementary File 2.



Figure 5. Conditional *HLA* association analysis. Upper panel: *HLA* association analysis for blood donorship. Middle panel: *HLA* association analysis for blood donorship adjusted for rs9272324-G. Lower panel: *HLA* association analysis for blood donorship adjusted for *HLA-DRB1**04:01. The other covariates used in all analyses were age, sex, BMI, PC1-10, birth region, and FinnGen genotyping array version. The dotted horizontal line represents the highest p-value that meets the FDR limit of 0.05.

Association of the GWAS lead variants with molecular traits

To better understand the functional effects of the 46 selected GWAS lead variants, we used quantitative trait locus (QTL) analysis for protein expression levels, metabolites, and common electronic health care record-derived laboratory value measurements as well as functional enrichment analysis. Altogether 470,490 associations were tested, and 327 pQTL and labQTL associations reached the significance level of FDR < 0.05. Among the 41 fine-mapped and five MHC

region variants, 19 were significantly associated with 184 unique plasma protein expression levels and 18 with 128 clinical laboratory value measurements (Table 3). However, no significant associations were observed between the 46 genetic variants and metabolite levels.

Since the proteomics data originated solely from the blood donor cohort, we were unable to analyze whether the significant pQTLs acted as mediators. In contrast, as the laboratory value measurement data comprised both blood donors and controls, we could perform a mediation analysis for the observed significant labQTLs. The analysis estimates the indirect effect of a genetic variant on blood donorship through a measured laboratory value.

			pQTL	labQTL
rs number	**Effect allele**	**Target gene**	**Associated with protein level alteration** (FDR < 0.05)	**Associated with laboratory value in a given category** (FDR < 0.05)
rs1135071	A	HBB	52 different proteins	Iron
rs199598395	T	RNF43	PARP1	Iron, liver function
rs8176058	A	KEL	APBB3, ETV5, NCR3, NT5M, TPH1, YTHDC1, KEL	-
rs191302298	C	LINC01411	21 different proteins	-
rs10096658	C	ZFPM2	14 different proteins	-
rs62113181	A	KDM4B	RXRA, SLMAP	-
rs9272324	G	HLA-DQA1*	HERC5, MICB, SH3GL3-1, HLA-DRA	Electrolytes, glucose, hemostasis, immune system, iron, lipids, thyroid gland function
rs60678519	A	AC079780 ,1	GPNMB, GPNMB-1, GPNMB-2	-
rs10947114	C	SFTA2*	DDR1	Hemostasis, iron, liver function
rs3130906	A	HCP5*	CDSN, TEK	Iron, thyroid gland function, immune system, lipids, electrolytes, hemostasis, glucose
rs34483988	T	FAM171B	-	Iron
rs6775319	A	SATB1-AS1	-	Glucose
rs3806234	A	SNAPIN	-	Immune system
rs4713637	C	LINC00336*	-	Iron, immune system, hemostasis
rs594398	G	SUMO2P17	-	Glucose
rs10166897	A	MAPRE3	CGREF1, KHK	-
rs113236240	T	PPCDC	PPCDC	-
rs9968910	C	HIST1H1C*	-	Iron, glucose, immune system, hemostasis
rs5821444	TTAA	C17orf58	-	Liver function, lipids, immune system
rs12444334	G	GAS8	CDH15	Iron, liver function
rs11675100	A	AC007100 ,1	-	Glucose
rs61937595	T	R3HDM2	INHBC, TDP1, IL21R	-
rs34811474	A	ANAPC4	-	Immune system, glucose
rs77448558	C	GRIK2*	ARCV1	-
rs10268629	T	TAC1*	NADK	Iron
rs687621	G	ABO	54 different proteins	Thyroid gland function, liver function, lipids, iron, immune system, hemostasis, glucose, electrolytes
rs55794721	A	SYF2	ICAM4, ICAM4-1	Immune system, hemostasis, iron, lipids
rs118101548	C	POLD1	15 different proteins	-

Table 3. Significant associations (FDR < 0.05) of quantitative trait locus analysis for protein expression level and clinical laboratory values with the GWAS fine-mapped and MHC lead variants. In case the target gene is not known, the nearest gene is indicated by asterisk (*).

Variants regulating protein expression levels

Two variants were shown to be associated with expression levels of more than 50 unique proteins (Supplementary Figure 2). rs-678621-G located on the *ABO* gene regulated expression levels of 54 proteins, and rs1135071-A in the *HBB* gene regulated 52 proteins. rs-678621-G pQTLs included proteins essential for the histo-blood group ABO formation, such as ABO itself and various N-acetylgalactosaminyltransferases such as GALNT9. Additionally, due to the enrichment of the rs687621-A allele in blood donors, decreased expression was observed for proteins such as F8 and MUC2, while the strongest increasing effect were seen for ALPI and SELE. Only two of the 52 associations identified with rs1135071-A showed decreasing effects on protein levels, the strongest effect was seen with TLR2, while the rest of the associations showed increasing effects, such as AHSP and MTIF3.

Other variants with more than 10 associations with protein expression levels included rs191302298-C (21 unique proteins), rs118101548-C (15 unique proteins) and rs10096658-C (14 unique proteins). In blood donors, the rs55794721-A variant exerted a decreasing effect on ICAM4, a LW glycoprotein present in the RhD protein complex. Additionally, a putative cancer-related protein association was observed for rs60678519-A and GPNMB. Due to the enrichment of rs60678519-AAAT in blood donors, GPNMB expression was decreased in blood donors. Overexpression of GPNMB has been linked to immunosuppression within the tumor immune microenvironment, leading to poorer prognosis in various cancers[24].

The STRING[25] functional enrichment analysis tool identified several Gene Ontology (GO) functional processes for the 184 proteins (Figure 6). Furthermore, the 54 proteins regulated by rs687621-G alone showed significant enrichments. Among the 184 proteins significantly associated with the 19 variants, GO revealed the enrichment of cell adhesion molecules in biological processes and signaling receptor activity in molecular functions. KEGG pathway enrichment was seen in cell adhesion molecules and mucin type O-glycan biosynthesis (Figure 6a, Supplementary file 3). Among

300 the 54 proteins associated with rs687621-G, enrichment was seen in the biological process of cell
301 adhesion and in molecular functions of antigen binding, transmembrane signaling receptor activity,
302 carbohydrate binding, signaling receptor activity, transmembrane receptor protein tyrosine kinase
303 activity and virion binding (Figure 6b).

304 We detected 60 pQTLs that were not involved with the enriched biological processes or pathways.
305 Of these, the strongest increasing and decreasing effect was seen with rs1135071-A on AHSP (beta =
306 2.59) and ACP6 (beta = -0.97), respectively (Supplementary Figure 2).

307



308

309 **Figure 6**. Enriched functional processes among the protein levels regulated by the 41 fine-mapped
310 and 5 MHC lead variants. **a)** KEGG pathway enrichments among the 181 significant QTL target
311 proteins. **b)** Five Gene Ontology (GO) functional processes enriched among the 54 proteins regulated
312 by rs687621-A located in *ABO*. Three variants were found to regulate these functional processes. The

associated variants and the effect alleles are shown on the x-axis and the proteins on the y-axis. The protein levels were measured in blood donors.

Variants regulating clinical laboratory test values

We observed 128 significant labQTLs that comprised nine variants and 50 different measurements and represented eight different clinical laboratory value categories (Supplementary File 4). Test of mediation for the top QTL of each 50 laboratory measurements showed significant mediation effect for 9 variants in 43 clinical laboratory measurements (Figure 7a). The highest number of mediated associations were seen in Iron (13 associations), Lipids (10 associations), Immune System (5 associations) and Liver Function (5 associations) related laboratory categories. The highest number of mediated associations, 16, on different laboratory values was seen for the MHC variant rs9272324. The results of the labQTL analysis are shown in detail in Supplementary File 4.

Strongest mediation effect, as measured by the proportion of mediated effect relative to the total SNP effect, was seen for iron related laboratory values. Glucose, hemostasis, lipids, immune and liver function related labQTLs also showed proportion of mediation > 0.2.

Of the 43 significant mediation effects, 25 showed lower and 18 higher clinical laboratory values in blood donors when compared to control population (Figure 7b). However, direction of the QTL effect on a laboratory value for the allele enriched in blood donors was sometimes opposite to the laboratory value difference between blood donors and controls. For example, blood donors had lower plasma ferritin levels (likely caused by donation), but they also harbored an enriched genetic variant that upregulates plasma ferritin.



335

336 **Figure 7**. Mediation analysis of labQTLs. The analysis estimates the indirect effect of a genetic variant
337 on blood donorship through a measured laboratory value. **a)** 43 significant mediation effects plotted
338 in the top right quarter as defined by FDR < 0.05 difference in a lab value between blood donors and
339 FinnGen controls adjusted for the QTL SNP (x-axis) and Sobel's mediation test (y-axis). FDR limits are
340 indicated by dashed lines. Proportion of mediation relative to the total effect of the variant is
341 depicted by symbol size. **b)** Barplot of lab values with a significant QTL. The y-axis shows lab value
342 effect sizes toward blood donorship, i.e. the effect size between blood donors and FinnGen controls
343 when adjusted for the QTL SNP. The labQTL direction for the allele enriched in blood donors is

depicted by the color bar on the x-axis. A lab measurement can have a lower value in blood donors than in controls (negative beta), but the QTL direction can still be up (or *vice versa*).

Putative bias caused by red cell antigen enrichment in research setting

Protective association of red cell antigen O to venous thromboembolism (VTE) has been shown previously by multiple studies[11–13]. To investigate the putative bias an ABO enrichment could cause to a VTE association study, we conducted an association analysis with VTE as an endpoint using chromosome 9 variants by adjusting for imputed ABO antigens. Our results showed that after the adjustment, the p-value of the lead variant failed to reach the genome-wide significance level of 5×10^{-8} (rs582118 unadjusted $p = 3.28 \times 10^{-115}$, ABO adjusted $p = 1.16 \times 10^{-6}$). The signal was not completely lost as other genome-wide significant variants remained in the region (Supplementary Figure 4A-B). The adjustment not only removed associations of some SNPs but also made visible other variants not detected in the basic analysis (Supplementary Figure 4C).

Discussion

The healthy donor effect is a well-documented phenomenon, but its genetic basis has remained unclear. In this study, we conducted a genome-wide comparison between blood donor biobank donors with relatively long and active blood donation history[14] and the FinnGen control population. The FinnGen controls included individuals from hospital biobanks, population cohorts, and patients at occupational health clinics. The latter two cohorts primarily comprise healthy individuals, and as disease-specific legacy cohorts were excluded from the analysis, the study controls are not ideal to but can be assumed to be not severely biased control population representing the general population of Finland.

367 The observed protection of blood donors from certain diseases can be directly attributed to donor
368 eligibility criteria that select healthy individuals. However, some of the observed protective genetic
369 factors may be secondary. For instance, the strongest negative genetic correlation was seen with
370 phenotype 'Anemias'. This correlation could be due to individuals with a higher tendency for
371 diseases causing iron loss being less likely to start donating blood or to withstand repeated
372 donations. Additionally, it may be a secondary result of autoimmune diseases, such as Crohn's
373 disease, which can restrict blood donation eligibility and lead to secondary anemia. Surprisingly, our
374 results reveal that blood donors not only exhibit a protective genetic profile against diseases
375 explicitly targeted by donor eligibility criteria, but also show a broader negative genetic correlation
376 with conditions beyond these criteria, including various mental illnesses, infectious diseases and
377 Alzheimer's disease. This suggests that blood donors harbor a lower genetic disease burden than the
378 general biobank population. While pleiotropic effects and/or self-selection may explain this
379 phenomenon, our analyses indicate that the genetic correlation with the phenotypes targeted by the
380 eligibility criteria is not consistently strong. Further detailed investigations are required to fully
381 understand pleiotropy in blood donor selection and to explore the potential benefits of an active
382 blood donor population for genetic and biomedical research.

383 Expectedly, genetic variants in the MHC region played strong role in several genetic associations and
384 in QTLs. HLA alleles with known autoimmune associations occurred with lower frequency in the
385 blood donor population than in the control population, whereas *HFE* C282Y-linked *HLA* alleles[14] and
386 *HLA* alleles with known protective role in autoimmunity were more frequent among the blood
387 donors. Furthermore, the negative selection for T1D in blood donors leading to lower frequency of
388 HLA-DQ2/8 genotype, could explain some of the protective genetic correlation. HLA-alleles of this
389 genotype, have known predisposing associations, including certain infectious diseases and use of
390 antidepressants[5]. These findings show the simultaneous genetic selection in the MHC for
391 hemochromatosis and against autoimmune conditions among blood donors, while the pleiotropic

392 role of the associated HLA alleles could explain some of the protective genetic correlation shown in
393 this study.

394 In addition to tagging certain autoimmune-related *HLA* alleles or haplotypes (e.g. T1D and ankylosing
395 spondylitis), rs9272324-G was shown to enhance the protein levels of *HLA-DRA*, which encodes the
396 nonpolymorphic *DR* alpha-chain[26], essential for the stable expression of DR molecules on the cell
397 surface. Considering this, the known associations of *HLA-DRB1*15:01* with multiple sclerosis[3,27]and
398 the lower frequency of the rs9272324-G in blood donors, further investigation of the pleiotropic role
399 of rs9272324 in multiple sclerosis and in autoimmunity in general would be of interest.

400 Furthermore, blood group antigen-related variants rs55794721 and rs687621 were found to
401 decrease the expression level of genes involved in the function or structure of the cognate blood
402 group molecules. These molecules include e.g. the RhD accessory protein ICAM4, the Landsteiner-
403 Wiener glycoprotein[8], and GALNT9, a type of N-acetylgalactosaminyltransferase necessary in the
404 conversion of the *H* antigen into blood type A in ABO biosynthesis[13,28–30].

405 In addition to hemochromatosis, the results of the present study highlight genetic factors that may
406 affect recipient matching or donation activity. We show an increasing expression level of AHSP
407 protein due to *Hb Tacoma* variant rs1135071-A. AHSP plays a crucial role in hemoglobin assembly by
408 stabilizing the αHb subunits and preventing the self-aggregation of excess αHb subunits prior the
409 formation of HbA1 subunit[31]. Given the speculated role of AHSP as a genetic modifier in β-
410 thalassemia[31,32] and the described normal clinical phenotype of *Hb Tacoma* heterozygotes[33],
411 rs1135071 could be of further interest in β-thalassemia research. Since the rs1135071-A allele is less
412 common in blood donors compared to controls and strongly downregulates Hb and methemoglobin,
413 it may be useful to analyze whether blood donation is harmless for *Hb Tacoma* heterozygotes or
414 whether the blood products are suitable for recipients with conditions such as sickle cell disease[34].

415 We demonstrated that blood donors differ from controls in several clinical blood laboratory
416 measurements, such as ferritin and lipoproteins, that are regulated by the 41 fine-mapped and 5
417 MHC lead variants. For example, consistently with low prevalence of diabetes, blood donors exhibit
418 lower plasma glucose levels, partly due to genetics, but also have higher LDL levels due to enriched
419 QTLs. Interestingly, HDL levels are higher in blood donors, despite the presence of a variant that
420 typically lowers HDL. This could be attributed to the U-shaped relationship between HDL and overall
421 health[35], where extremely high HDL levels are harmful and thus less common among blood donors.
422 Our mediation analysis also revealed that blood donors had lower ferritin and higher hemoglobin
423 levels than controls. This finding is in line with our previous studies; donation activity is a major
424 determinant of ferritin in donors[36], yet iron deficiency anemia is less common in donors (0.5 %) than
425 in the Finnish general population (2.6 %)[37]. Consistent with this result, blood donors exhibited an
426 enrichment of a compensatory variant that upregulates ferritin levels.

427 In this study we present the genetic underpinnings of HDE and blood group-based selection in active
428 blood donors. Our findings highlight the unique genetic makeup of this donor population and its
429 impact on health and blood donation suitability. The results demonstrate the role of genetics in
430 maintaining good health status and active blood donation career which is also connected to genetic
431 variation associated with a good mental health. Furthermore, research using blood donors as a
432 control group should account for this distinct genetic structure, even after donation ceases.
433 Additionally, the relatively predominant enrichment of specific blood group antigens among blood
434 donors warrants consideration in research as these antigens have several known disease
435 associations. No unambiguous solution exists to control collider biases when conducting research
436 within blood donors, but rather a case-by-case evaluation e.g. through directed acyclic graphs can be
437 helpful when evaluating the possibility of collider biases[38–40]. Further investigations are necessary to
438 fully elucidate the implications of these discoveries, but they underscore the genetic structure

behind HDE and the potential of active blood donor cohorts for advancing biomedical genetic research.

Material and Methods

Ethics statement

Study subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were collected based on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea (Finnish Medicines Agency), the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) statement number for the FinnGen study is Nr HUS/990/2017. Full list of permits numbers are listed in Supplementary information.

All the sample donors had given a written biobank consent. The use of the data in the present study is in accordance with the biobank consent and meets the requirements of the Finnish Biobank Act 688/2012. A formal biobank decision 004-2022 for the research project has been granted by the Finnish Red Cross Blood Service Biobank. The use of the FinnGen data has been accepted with FinnGen proposal F_2022_086.

Data acquisition

Genome data used in the present study originated from samples that were genotyped in the FinnGen project with the FinnGen ThermoFisher Axiom custom array v1 or v2 and genome imputation version R12. Genotyping, quality control, and genome imputation protocols are

461 described in detail in FinnGen Gitbook (https://finngen.gitbook.io/documentation/). In short,
462 genotype calling was performed with GenCall or zCall algorithm for Illumina and AxiomGT1
463 algorithm for Affymetrix arrays. Prior the imputation, genotyped samples were pre-phased with
464 Eagle 2.3.5 with the default parameters, except the number of conditioning haplotypes was set to
465 20,000. Genotype imputation was performed using the population-specific imputation reference
466 panel SISu v4.2 with Beagle 4.1 (version 27Jan18.7e1).

467 In addition to genome and phenotype data, the following electronic health register data and
468 supplementing data were utilized: KANTA clinical laboratory values, ICD (ICD9 and 10) code for type
469 1 diabetes, occurrence of venous thromboembolism, age, BMI, sex, region of birth and genetic
470 principal components (PC) 1-10.

471 To minimize potential bias in downstream analyses, legacy samples
472 (https://finngen.gitbook.io/documentation/), highly enriched in certain common diseases, were
473 excluded from the study controls due to the known selection of healthy individuals as blood donors.
474 Individuals under 18 years of age were removed, as 18 is the minimum age of blood donation. In
475 addition, individuals born in regions in Finland that were ceded to Soviet Union were excluded due
476 to age structure of the region and the maximum blood donation age of 70 years. As BMI might
477 influence donor eligibility, individuals lacking BMI information were filtered out. After filtering, total
478 number of FinnGen genome data used in this study was 53,688 cases (blood donors) and 228,060
479 controls (other FinnGen participants).

480 Statistical analyses

481 If not stated otherwise, all statistical analyses were performed in R[41] version 4.3 or 4.4, with
482 RStudio[42]. The genome-wide significance p-value threshold $p < 5 \times 10^{-8}$ was used in GWAS. In all
483 other analyses, p-values were adjusted with the Benjamini–Yekutieli procedure[43], and significance
484 threshold of 0.05 was used. All the phenotypes analyzed here have been described in FinnGen DF12

485 dataset. The FinnGen summary statistics data are publicly available (https://r12.finngen.fi/)[18], and
486 the methods are available at https://finngen.gitbook.io/documentation/methods/.

487 Association analysis and fine-mapping

488 Genome-wide association study, GWAS, using an additive genetic model, was performed in FinnGen
489 pipeline with Regenie[44] (https://github.com/FINNGEN/regenie-pipelines) v2.2.4 with blood donor
490 status as a binary endpoint. Sex, age, BMI, PC1-10, birth region, and FinnGen genotyping array
491 version were used as covariates in the GWAS. To discover associations independent of type 1
492 diabetes (T1D) in chromosome 6, the FinnGen T1D endpoint[45] was used as an additional covariate in
493 the chromosome 6-specific association analysis.

494 Fine-mapping for the genome-wide significant GWAS signals ($p < 5 \times 10^{-8}$) was performed in FinnGen
495 pipeline (https://github.com/FINNGEN/) with SuSiE[46] excluding MHC region (GRCh38, chr6:25-34
496 Mb)[45,47]. For each fine-mapped locus we accepted the credible set as an independent hit if the
497 strongest primary p-value was $p < 5 \times 10^{-8}$. In case multiple credible sets within a single locus were
498 found, we required genome-wide significance and $\log_{10}$(Bayes factor) > 2. As the MHC region is
499 excluded from the fine-mapping pipeline due to its strong LD, four MHC lead variants from the T1D
500 adjusted association analysis were selected for downstream analyses: rs9968910, rs10947114,
501 rs3130906 and rs4713637. Moreover, the lead variant in the MHC region in the non-T1D adjusted
502 GWAS, rs9272324, was included in the further analyses due to its strong association with
503 autoimmunity[18].

504 Association analyses with the blood donor endpoint for all the covariates used in GWAS and the
505 imputed blood groups were performed with logistic regression in R. We further analyzed the
506 associations of all the covariates used in GWAS and the imputed blood group antigens with the lead
507 variants in chromosomes 1 (rs55794721), 7 (rs8176058) and 9 (rs687621) by using linear regression.

508 Association testing of each classical *HLA* allele *HLA-A*, *-B*, *-C*, *-DRB1*, *-DQA1*, *-DQB1*, *DPB1* and *HLA-*
509 *DRB3-5* with the blood donor endpoint was performed using Regenie v3.0.1. First, a sparse genotype
510 data set for fitting Regenie null models (https://rgcgithub.github.io/regenie/options/) was generated
511 with Plink2 v2.00a4LM using FinnGen DF12 HapMap3 variants as a basis, and randomly thinning the
512 variants to approximately 500,000 with further filtering for minor allele frequency at least 0.1,
513 Hardy-Weinberg equilibrium p-value > 1×10^{-15} and minimum allele count at least 100. Second, the
514 Regenie null models were fitted on the filtered genotype data and used in the following association
515 step. To dissect the HLA signal further, two additional association tests were performed: i)
516 conditioning for the GWAS chromosome 6 lead variant rs9272324 and ii) conditioning for the HLA
517 allele with the strongest association, *HLA-DRB1*04:01*, in the primary HLA association analysis.

518 Since both the GWAS lead variant rs687621 in chromosome 9 and the red cell antigen ABO have
519 previously been reported to be strongly associated with venous thromboembolism[45](VTE), we
520 sought to study whether ABO enrichment in the blood donor pool and the lead variant associate
521 independently with VTE. To this end, we conducted an association analysis of chromosome 9 in
522 FinnGen pipeline using Regenie[44] (https://github.com/FINNGEN/regenie-pipelines) v2.2.4 with
523 FinnGen venous thromboembolism as the binary endpoint. Sex, age, PC1-10, FinnGen genotyping
524 array version, and FinnGen batch information were used as covariates, as well as imputed ABO red
525 cell antigens. After filtering out 20 individuals based on low posterior probability of the imputed ABO
526 antigens, 19,956 cases and 344,653 controls remained in the conditional analysis.

527 Genetic correlation

528 All pair-wise genetic correlations between blood donorship and all the 2470 phenotypes previously
529 studied as part of FinnGen study were computed using LD Score Regression v1.0.1 using Finnish LD
530 panel in FinnGen pipeline (https://github.com/FINNGEN/)[48]. The computation was based on the
531 GWAS summary statistics previously obtained using Regenie for each phenotype. We used the
532 Benjamini-Yekutieli method to control FDR of genetic correlation at the level of 0.05. Genetic

correlation between groups of phenotypes was approximated as the average of all the pair-wise genetic correlations between the groups.

HLA and blood group imputation

The alleles of the classical HLA genes, *HLA-A*, *-C*, *-B*, *-DRB1*, *DRB3-5*, *-DQA1*, *-DQB1*, and *-DPB1*, were previously imputed at four-field resolution (defining protein sequence variation) in FinnGen using HIBAG[49] algorithm with population-specific reference panel, as reported earlier[50]. The dosage value of each HLA-allele was used in downstream analyses.

Altogether 37 red blood cell antigens in 14 different blood group systems were imputed using population-specific random forest models as described by Hyvärinen et al[51]. *P1*, *A1* and *A2* antigens were excluded from downstream analyses due to uncertain frequency at the population level. In addition, blood group antigens *HrS* and *HrB*, occurring mainly in African population, are in high correlation with the blood group antigen *e* and have low clinical significance (consultation with an expert at the Finnish Red Cross Blood Service), hence they were excluded from further analyses. After imputation, the samples were categorized based on the posterior probability, PP, value; samples with PP < 0.5 were considered as antigen negative and samples with PP ≥ 0.5 were considered as antigen positive. Altogether 13 individuals were excluded from downstream blood group related analyses due to all PP values in ABO being < 0.5.

QTL analysis

Proteomics data were previously generated in FinnGen on blood donors using multiplex antibody-based immunoassay (Olink) and multiplex aptamer-based immunoassay (SomaScan)[52]. We analyzed protein QTLs by performing an association analysis between 46 GWAS lead variants and protein expression data using glm function of Plink2 v2.00a4LM. Age, sex, sampling year and PC1-10 were used as covariates in the association analysis, and first-degree relatives were removed. To evaluate

556 the enrichment of the associated proteins in functional processes, we used STRING interaction
557 network and functional enrichment analysis tool[25].

558 We also analyzed metabolite level data produced by Nightingale NMR platform
559 (https://research.nightingalehealth.com/) in FinnGen. The data were preprocessed by selecting
560 variables that were common between all available data files, removing duplicated sample IDs, and
561 removing variables with >500 missing entries. The association analysis between cleaned NMR data
562 and lead GWAS variants was performed as described above for proteomics.

563 The KANTA clinical laboratory test data in FinnGen spans from 2014 to 2023, as detailed in the
564 FinnGen documentation (https://finngen.gitbook.io/finngen-handbook). Laboratory values were
565 extracted for each individual in this study, comprising 53,688 blood donors and 228,060 controls.
566 Missing values were excluded, retaining measurements with n > 100,000. The data were then
567 cleaned by removing measurements > 5 standard deviations from the population mean. To obtain a
568 single value per variable for each individual, we computed the geometric mean over time. To
569 account for temporal changes in lab values, we also calculated the slope for each variable and
570 individual. Finally, each variable was transformed into a standard normal distribution using quantile
571 normalization.

572 We tested the associations of the 46 GWAS lead variants with the laboratory values using
573 continuous regression analysis, adjusting for age, sex, sampling year, and PC1-10 as covariates using
574 the glm function in Plink2. Laboratory values with a significant QTL (FDR < 0.05) were included in
575 follow-up analyses. For mediation analysis[53], we selected significant labQTLs limiting to the smallest
576 p-value per each KANTA lab value, and included both the SNP and the corresponding KANTA lab
577 value as independent variables in a logistic regression model of blood donorship. We accepted lab
578 value associations reaching FDR < 0.05, indicating that these values associate with blood donorship
579 when adjusted for their QTL SNPs. To further validate the causal effect of each GWAS lead variant on

KANTA laboratory values, we employed the Sobel mediation test[54] using the R package bda v18.3.2, accepting FDR < 0.05.

Data Availability

FinnGen summary statistics and other information are available at https://r12.finngen.fi/. Data supporting the current study are available from the authors upon reasonable request and with permission of FinnGen.

The GWAS summary statistics for the blood donor phenotype will be available at a public repository to be determined later.

Code Availability

Code will be available in https://github.com/FRCBS/HDE-GWAS.

References

1. Finnish Red Cross Blood Service - donation eligibility. https://www.veripalvelu.fi/en/faq/?search=&category=eligibility.
2. Hu, X. *et al.* Additive and interaction effects at three amino acid positions in HLA-DQ and HLA-DR molecules drive type 1 diabetes risk. *Nat. Genet.* **47**, 898–905 (2015).
3. De Silvestri, A. *et al.* The Involvement of HLA Class II Alleles in Multiple Sclerosis: A Systematic Review with Meta-analysis. *Dis. Markers* **2019**, 1409069 (2019).
4. Dendrou, C. A., Petersen, J., Rossjohn, J. & Fugger, L. HLA variation and disease. *Nat. Rev. Immunol.* **18**, 325–339 (2018).
5. Ritari, J., Koskela, S., Hyvärinen, K., FinnGen & Partanen, J. HLA-disease association and pleiotropy landscape in over 235,000 Finns. *Hum. Immunol.* **83**, 391–398 (2022).
6. Atsma, F., Veldhuizen, I., Kort, W. De & Vegt, F. De. Healthy donor effect: its magnitude in health research among blood donors. *Transfusion* **51**, 1820–1828 (2011).
7. Marsh, W. L. & Redman, C. M. The Kell blood group system: a review. *Transfusion* **30**, 158–167 (1990).

609 8. Avent, N. D. & Reid, M. E. The Rh blood group system: a review. *Blood* **95**, 375–387 (2000).

610 9. Levine, P. & Stetson, R. E. Landmark article July 8, 1939. An unusual case of intra-group
611 agglutination. By Philip Levine and Rufus E Stetson. *JAMA* **251**, 1316–1317 (1984).

612 10. GIBLETT, E. R. A critique of the theoretical hazard of inter vs. intra-racial transfusion.
613 *Transfusion* **1**, 233–238 (1961).

614 11. Stowell, S. R. & Stowell, C. P. Biologic roles of the ABH and Lewis histo-blood group antigens
615 part II: thrombosis, cardiovascular disease and metabolism. *Vox Sang.* **114**, 535–552 (2019).

616 12. Dahlén, T., Clements, M., Zhao, J., Olsson, M. L. & Edgren, G. An agnostic study of associations
617 between ABO and RhD blood group and phenome-wide disease risk. *Elife* **10**, (2021).

618 13. Ward, S. E., O'Sullivan, J. M. & O'Donnell, J. S. The relationship between ABO blood group,
619 von Willebrand factor, and primary hemostasis. *Blood* **136**, 2864–2874 (2020).

620 14. Clancy, J. *et al.* Blood donor biobank as a resource in personalised biomedical genetic
621 research. *Eur. J. Hum. Genet.* (2024) doi:10.1038/s41431-023-01528-0.

622 15. Mitchell, R. Blood banks, biobanks, and the ethics of donation. *Transfusion* **50**, 1866–1869
623 (2010).

624 16. Raivola, V., Snell, K., Helén, I. & Partanen, J. Attitudes of blood donors to their sample and
625 data donation for biobanking. *Eur. J. Hum. Genet.* **27**, 1659–1667 (2019).

626 17. Raivola, V., Snell, K., Helen, I. & Partanen, J. Attitudes of blood donors to their sample and
627 data donation for biobanking. *Eur. J. Hum. Genet.* **27**, 1659–1667 (2019).

628 18. FinnGen. FinnGen Result Browser. https://r10.finngen.fi/ (2024).

629 19. National Institutes of Health LDlink. https://ldlink.nih.gov/?tab=home.

630 20. ISBT Blood Group Allele Tables. https://www.isbtweb.org/isbt-working-parties/rcibgt/blood-
631 group-allele-tables.html.

632 21. Li, S. & Schooling, C. M. A phenome-wide association study of ABO blood groups. *BMC Med.*
633 **18**, 334 (2020).

634 22. Bowness, P. HLA-B27. *Annu. Rev. Immunol.* **33**, 29–48 (2015).

635 23. Simmons, K. M. *et al.* Failed Genetic Protection: Type 1 Diabetes in the Presence of HLA-
636 DQB1*06:02. *Diabetes* **69**, 1763–1769 (2020).

637 24. Lazaratos, A.-M., Annis, M. G. & Siegel, P. M. GPNMB: a potent inducer of
638 immunosuppression in cancer. *Oncogene* **41**, 4573–4590 (2022).

639 25. Szklarczyk, D. *et al.* The STRING database in 2023: protein-protein association networks and
640 functional enrichment analyses for any sequenced genome of interest. *Nucleic Acids Res.* **51**,
641 D638–D646 (2023).

642 26. Brown, J. H. *et al.* Three-dimensional structure of the human class II histocompatibility
643 antigen HLA-DR1. *Nature* **364**, 33–39 (1993).

644 27. Goodin, D. S., Khankhanian, P., Gourraud, P.-A. & Vince, N. Highly conserved extended
645 haplotypes of the major histocompatibility complex and their relationship to multiple
646 sclerosis susceptibility. *PLoS One* **13**, e0190043 (2018).

647 28. Stowell, C. P. & Stowell, S. R. Biologic roles of the ABH and Lewis histo-blood group antigens
648 Part I: infection and immunity. *Vox Sang.* **114**, 426–442 (2019).

649 29. Sayers, E. W. *et al.* Database resources of the national center for biotechnology information.
650 *Nucleic Acids Res.* **50**, D20–D26 (2022).

651 30. Daniels, G. The molecular genetics of blood group polymorphism. *Hum. Genet.* **126**, 729–742
652 (2009).

653 31. Che Yaacob, N. S., Islam, M. A., Alsaleh, H., Ibrahim, I. K. & Hassan, R. Alpha-hemoglobin-
654 stabilizing protein (AHSP): a modulatory factor in β-thalassemia. *Int. J. Hematol.* **111**, 352–
655 359 (2020).

656 32. dos Santos, C. O. & Costa, F. F. AHSP and beta-thalassemia: a possible genetic modifier.
657 *Hematology* **10**, 157–161 (2005).

658 33. Giardine, B. *et al.* Updates of the HbVar database of human hemoglobin variants and
659 thalassemia mutations. *Nucleic Acids Res.* **42**, D1063-9 (2014).

660 34. Rutherford-Parker, N. J., Colby, J. M., Gehrie, E. A. & Booth, G. S. Unrecognized Hemoglobin
661 Variants in the Donor Blood Supply Are Detectable in the Transfused Population. *Am. J. Clin.*
662 *Pathol.* **154**, 494–498 (2020).

663 35. Bonacina, F., Pirillo, A., Catapano, A. L. & Norata, G. D. HDL in Immune-Inflammatory
664 Responses: Implications beyond Cardiovascular Diseases. *Cells* **10**, (2021).

665 36. Lobier, M. *et al.* The effect of donation activity dwarfs the effect of lifestyle, diet and targeted
666 iron supplementation on blood donor iron stores. *PLoS One* **14**, e0220862 (2019).

667 37. Toivonen, J., Allara, E., Castrén, J., di Angelantonio, E. & Arvas, M. The value of genetic data
668 from 665,460 individuals in managing iron deficiency anaemia and suitability to donate
669 blood. *Vox Sang.* **119**, 34–42 (2024).

670 38. Lee H, Aronson JK, N. D. Catalogue of bias collaboration. *Collider bias. In Catalogue Of Bias.*
671 https://catalogofbias.org/biases/collider-bias/ (2019).

672 39. Tönnies, T., Kahl, S. & Kuss, O. Collider Bias in Observational Studies. *Dtsch. Arztebl. Int.* **119**,
673 107–122 (2022).

674 40. Digitale, J. C., Martin, J. N., Glidden, D. V & Glymour, M. M. Key concepts in clinical
675 epidemiology: collider-conditioning bias. *J. Clin. Epidemiol.* **161**, 152–156 (2023).

676 41. R Core Team. https://www.r-project.org/.

677 42. R studio. https://www.rstudio.com/.

678 43. Benjamini, Y. & Yekutieli, D. The control of the false discovery rate in multiple testing under
679 dependency. *Ann. Stat.* **29**, 1165–1188 (2001).

680 44. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and
681 binary traits. *Nat. Genet.* **53**, 1097–1103 (2021).

682 45. Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated
683 population. *Nature* **613**, 508–518 (2023).

684 46. Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A Simple New Approach to Variable
685 Selection in Regression, with Application to Genetic Fine Mapping. *J. R. Stat. Soc. Ser. B Stat.*
686 *Methodol.* **82**, 1273–1300 (2020).

687 47. FinnGen. FinnGen Documentation of data release.
688 https://finngen.gitbook.io/documentation/ (2024).

689 48. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in
690 genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).

691 49. Zheng, X. *et al.* HIBAG - HLA genotype imputation with attribute bagging. *Pharmacogenomics*
692 *J.* **14**, 192–200 (2014).

693 50. Ritari, J. *et al.* Increasing accuracy of HLA imputation by a population-specific reference panel

in a FinnGen biobank cohort. *NAR Genomics Bioinforma.* **2**, (2020).

51. Hyvärinen, K. *et al.* A machine-learning method for biobank-scale genetic prediction of blood group antigens. *PLoS Comput. Biol.* **20**, e1011977 (2024).

52. Suhre, K., McCarthy, M. I. & Schwenk, J. M. Genetics meets proteomics: perspectives for large population-based studies. *Nat. Rev. Genet.* **22**, 19–37 (2021).

53. VanderWeele, T. J. Mediation Analysis: A Practitioner's Guide. *Annu. Rev. Public Health* **37**, 17–32 (2016).

54. Preacher, K. J. & Hayes, A. F. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. *Behav. Res. Methods* **40**, 879–891 (2008).

Acknowledgements

We want to acknowledge the participants and investigators of FinnGen study. The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb (and Celgene Corporation & Celgene International II Sàrl), Genentech Inc., Merck Sharp & Dohme LCC, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, Novartis Pharma AG, and Boehringer Ingelheim International GmbH. Following biobanks are acknowledged for delivering biobank samples to FinnGen: Auria Biobank (www.auria.fi/biopankki), THL Biobank (www.thl.fi/biobank), Helsinki Biobank (www.helsinginbiopankki.fi), Biobank Borealis of Northern Finland (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx), Finnish Clinical Biobank Tampere (www.tays.fi/en-US/Research_and_development/Finnish_Clinical_Biobank_Tampere), Biobank of Eastern Finland (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-FI/Potilaalle/Biopankki), Finnish Red Cross Blood Service Biobank (www.veripalvelu.fi/verenluovutus/biopankkitoiminta), Terveystalo Biobank (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/) and Arctic Biobank (https://www.oulu.fi/en/university/faculties-and-units/faculty-medicine/northern-finland-birth-cohorts-and-arctic-biobank). All Finnish Biobanks are members of BBMRI.fi

infrastructure (www.bbmri.fi). Finnish Biobank Cooperative -FINBB (https://finbb.fi/) is the coordinator of BBMRI-ERIC operations in Finland. The Finnish biobank data can be accessed through the Fingenious® services (https://site.fingenious.fi/en/) managed by FINBB.

In addition, we want to acknowledge Dr Katri Haimila for her valuable advice with red cell antigen immunogenetics, Dr Kati Hyvärinen for her expertise and kind help with red cell antigen imputation and the personnel of Blood Service Biobank for their kind help and support for the study.

Author Contributions

Original study concept by JC and JR. Genetic and statistical analysis of the study: JC, JT, MA and JR. Visualization: JC, JT and JR. Medical expertise: JL. FinnGen: data curation and resources. Contributed to the study design: JC, JR, JT, MA, SK, JP. Original manuscript: JC. All the authors read, commented, and approved the final manuscript.

Competing Interests

The authors declare no competing interests.